Snapshot: May Highlights
A selection of articles you might have missed from May 2022, including exclusive interviews, an in depth discussion about China's rise to become one of the world's leaders in R&D, and the latest Rising Leaders interviews.
You may also be interested in...
SonALAsense has received Safe to Proceed letters from the FDA to begin trials of its ultrasound-activated cancer killing drug.
A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.
The Memorial Sloan Kettering spin-out has received CE-IVD and UKCA marks for its artificial intelligence software designed to identify HER2 expression in biopsies.